Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q13641
UPID:
TPBG_HUMAN
Alternative names:
5T4 oncofetal antigen; 5T4 oncofetal trophoblast glycoprotein; M6P1; Wnt-activated inhibitory factor 1
Alternative UPACC:
Q13641; A8K555
Background:
The Trophoblast glycoprotein, known by alternative names such as 5T4 oncofetal antigen and Wnt-activated inhibitory factor 1, plays a crucial role in cellular processes. It is identified by the unique identifier Q13641 and is implicated in modulating Wnt/beta-catenin signaling. This modulation is achieved through its indirect interaction with LRP6, which prevents the internalization of Wnt3a, thus acting as a signaling inhibitor.
Therapeutic significance:
Understanding the role of Trophoblast glycoprotein could open doors to potential therapeutic strategies. Its involvement in the Wnt/beta-catenin pathway, a key regulator of cell proliferation and differentiation, highlights its potential as a target for therapeutic intervention in diseases where this pathway is dysregulated.